Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.55)
# 271
Out of 5,105 analysts
113
Total ratings
54.08%
Success rate
26.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $114 → $141 | $113.56 | +24.16% | 10 | Dec 12, 2025 | |
| WVE Wave Life Sciences | Maintains: Buy | $19 → $40 | $16.56 | +141.55% | 2 | Dec 9, 2025 | |
| GUTS Fractyl Health | Maintains: Buy | $6 → $8 | $2.24 | +257.14% | 2 | Nov 21, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $90 → $148 | $98.58 | +50.13% | 7 | Nov 13, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 → $10 | $5.43 | +84.16% | 3 | Aug 18, 2025 | |
| PASG Passage Bio | Maintains: Buy | $260 → $67 | $9.80 | +584.02% | 7 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $5.79 | +141.80% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $36.23 | +253.30% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $452.04 | -9.08% | 9 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $397.55 | +4.39% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $3.39 | +194.99% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $9.02 | +498.67% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $7.46 | +784.72% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $0.85 | +605.88% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $21.53 | +596.70% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $53.31 | +57.57% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $120.40 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $6.95 | +3,353.24% | 4 | Jul 23, 2019 |
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $114 → $141
Current: $113.56
Upside: +24.16%
Wave Life Sciences
Dec 9, 2025
Maintains: Buy
Price Target: $19 → $40
Current: $16.56
Upside: +141.55%
Fractyl Health
Nov 21, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $2.24
Upside: +257.14%
Palvella Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $90 → $148
Current: $98.58
Upside: +50.13%
Generation Bio Co.
Aug 18, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.43
Upside: +84.16%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $9.80
Upside: +584.02%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $5.79
Upside: +141.80%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $36.23
Upside: +253.30%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $452.04
Upside: -9.08%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $397.55
Upside: +4.39%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.39
Upside: +194.99%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $9.02
Upside: +498.67%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $7.46
Upside: +784.72%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $0.85
Upside: +605.88%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $21.53
Upside: +596.70%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $53.31
Upside: +57.57%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $120.40
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $6.95
Upside: +3,353.24%